Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1994-08-24
1998-07-14
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
A61R 3166
Patent
active
057804559
ABSTRACT:
Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
REFERENCES:
patent: 4922007 (1990-05-01), Kieczykowski et al.
patent: 4927814 (1990-05-01), Gall
patent: 5019651 (1991-05-01), Kieczykowski
patent: 5462932 (1995-10-01), Brenner
Remington, Pharmaceutical Sciences, 18th Ed., pp. 1549-1550.
Nussbaum, (J. Clinical Oncology, 11(8), 1619) Aug. 1993.
Averbuch, (Cancer Supplement 72(11), 3444-52) Dec. 1993.
De Marco, et al., J. Pharm. Biomed. Anal. 7(12), 1719-27 1989.
"New Bisphosphonates in the Treatment of Bone Metastases" by Steven D. Averbuch, Cancer Supplement vol. 72, No. 11, Dec. 1, 1993, pp. 3444-3452.
"Dose-Response Study of Alendronate Sodium for the Treatment of Cancer-Associated Hypercalcemia" by S. R. Nussbaum, et al., Journal of Clinical Oncology, vol. 11, No. 8 (Aug.) 1993, pp. 1618-1623.
United States Pharmacopeia/National Formulary for 1995, "General Tests and Assays" Water for Injection, pp. 1636-1637.
United States Pharmacopeia/National Formulary for 1995, "General Tests and Assays" Sterility, pp. 1686-1690.
United States Pharmacopeia/National Formulary for 1995, "General Tests and Assays" Pyrogen, pp. 1718-1719.
United States Pharmacopeia/National Formulary for 1995, "General Tests and Assays" Particulates, pp. 1813-1819.
United States Pharmacopeia/National Formulary for 1995, "General Tests and Assays" Tonicity, p. 1813.
United States Pharmacopeia/National Formulary for 1995, "General Tests and Assays" pH, pp. 1819-1820.
Nussbaum, et al., J. Clinical Oncology, vol. 11, No. 8 (Aug. 1993): pp. 1618-1623.
Physicians' Desk Reference, 1996, pp. 1488 and 810.
Fleisch, H. Bisphosphonates -Pharmacology and Use in the Treatment of Tumour-Induced Hypercalcaemic and Metastatic Bone Disease-Drugs 42(6) 1991 pp. 919-944.
Brenner Gerald S.
Ghannam Musa M.
Gerstl Robert
Merck & Co. , Inc.
Sabatelli Anthony D.
Winokur Melvin
LandOfFree
Intravenous alendronate formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intravenous alendronate formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intravenous alendronate formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1881883